ABSTRACT The next-generation aminoglycoside plazomicin, in development for infections due to multidrug-resistant (MDR) Enterobacteriaceae, was evaluated alongside comparators for bactericidal activity in minimum bactericidal concentration (MBC) and time-kill (TK) assays against MDR Enterobacteriaceae isolates with characterized aminoglycoside and ␤-lactam resistance mechanisms. Overall, plazomicin and colistin were the most potent, with plazomicin demonstrating an MBC 50/90 of 0.5/4 g/ml and sustained 3-log 10 kill against MDR Escherichia coli, Klebsiella pneumoniae, and Enterobacter spp.
were dissolved in accordance with Clinical and Laboratory Standards Institute (CLSI) guidelines (12) .
The MIC and MBC values for plazomicin and comparators were determined by broth microdilution in accordance with CLSI guidelines (12) (13) (14) . For MBC determinations, duplicate 10-l aliquots from the MIC well and from three wells above the MIC were sampled for CFU enumeration. The MBC was defined as the concentration of drug that resulted in Ն3-log 10 CFU/ml decrease (99.9% kill) after an overnight incubation. MBC: MIC ratios were determined, and MBC:MIC ratios of Յ4 were considered indicative of bactericidal activity (15) .
The time-kill kinetics of plazomicin (at 2-, 4-, 8-, and 16-fold the MIC), amikacin, gentamicin, meropenem, and colistin (at 8-fold the MIC) against 10 isolates (three E. coli, including ATCC 25922, four Klebsiella spp., and three Enterobacter spp.) were determined per CLSI guidelines (14) . For isolates with MIC values of Ͼ8 g/ml, a concentration of 64 g/ml was used. After inoculation and sampling for a baseline viable count, flasks with the appropriate drug concentrations were incubated at 35°C with shaking. The flasks were sampled at specified time points for the determination of viable counts. Bactericidal activity was defined as a 3-log 10 decrease in CFU/ml relative to the starting inoculum maintained through 24 h. The MIC 50/90 and MBC 50/90 values, as well as the MBC:MIC ratios and percent susceptibilities overall and by species, for plazomicin and comparator agents are shown in Table 1 . Against all isolates, plazomicin displayed an MIC 50/90 of 0.5/2 g/ml and an MBC 50/90 of 0.5/4 g/ml, with an MBC:MIC ratio of Յ4 for 29 of 30 isolates (96.7%). In contrast, amikacin and gentamicin both demonstrated an MIC 50/90 value of 32/128 g/ml against these isolates. Amikacin had an MBC 50/90 of 64/256 g/ml and an MBC:MIC ratio of Յ4 for 96.7% of isolates; gentamicin had an MBC 50/90 of 64/Ͼ512 g/ml and an MBC:MIC ratio of Յ4 for 92.6% of isolates. As the majority of the isolates were resistant to these aminoglycosides, the MBCs for gentamicin and amikacin are not clinically relevant, despite the low MBC:MIC ratios.
Ceftazidime and meropenem had MIC 50/90 values of 64/Ͼ512 and 0.06/64 g/ml, respectively, against the tested isolates. The MBC 50/90 for ceftazidime was 128/Ͼ512 g/ml; that for meropenem was 0.12/64 g/ml, with MBC:MIC ratios of Յ4 for 100% of values. Levofloxacin had an MIC 50/90 of 16/64 g/ml and an MBC 50/90 of 16/64 g/ml, with an MBC:MIC ratio of Յ4 for 96.7% of isolates. Tigecycline and colistin had MIC 50/90 values of 0.5/4 and 0.12/0.25 g/ml, respectively, against these Enterobacteriaceae. Tigecycline was generally bacteriostatic by MBC, with an MBC 50/90 of Ͼ4/Ͼ16 g/ml and an MBC:MIC ratio of Ͼ4 against 75.9% of isolates. Colistin was bactericidal with an MBC 50/90 of 0.12/0.5 and an MBC:MIC ratio of Յ4 for all isolates.
Plazomicin and comparators were evaluated by a time-kill assay against a subset of isolates as shown in Table 2 ; the results for plazomicin are shown in Fig. 1 . A summary of the time-kill results for comparators is shown in Fig. S1 . At Ն4-fold the MIC against the E. coli isolates (Fig. 1a) , plazomicin was rapidly bactericidal for up to 6 h, but there was regrowth at doses Ͻ16-fold MIC through 24 h. Against ECO001/ATCC 25922, amikacin (through 24 h) and gentamicin (only to 6 h) showed cidal activity. Colistin showed rapid Ͼ3-log 10 CFU killing against all three strains out to 6 h and against the ECO1143 and ECO156 strains through 24 h. Against the three Klebsiella pneumoniae isolates, plazomicin demonstrated Ͼ3-log 10 CFU killing within 1 h at Ն4-fold the MIC through 24 h (Fig. 1b) . Amikacin and gentamicin showed rapid killing against KPN1158 but no activity against KPN1152; amikacin demonstrated killing against KPN1149 as well. Colistin was rapidly cidal only through 6 h against all three K. pneumoniae isolates. Plazomicin demonstrated 2-log 10 to 3-log 10 CFU killing by 6 h at all concentrations against the Klebsiella oxytoca isolate, similar to amikacin, which was bactericidal at 6 h; gentamicin was not bactericidal at any time point. Colistin showed bactericidal activity through 6 h against KOX1006 with regrowth at 24 h. Plazomicin demonstrated Ͼ3-log 10 killing against the Enterobacter aerogenes isolate EAE1025 at all concentrations through 6 h without regrowth through 24 h at concentrations Ն8-fold the MIC. Similarly, against the two Enterobacter cloacae isolates ECL1059 and ECL1060, plazomicin was bactericidal at concentrations Ն4-fold the MIC. Amikacin and gentamicin showed 3-log 10 CFU killing through 6 and 24 h, respectively, against EAE1025 and ECL1060. For colistin, bactericidal activity was observed through 6 h for EAE1025, but cidality was observed for 4 h against ECL1059 and ECL1060.
Here, plazomicin demonstrated potent bactericidal activity against aminoglycoside- and ␤-lactam-resistant MDR Enterobacteriaceae isolates. By MBC 50/90 and by MBC:MIC ratios, plazomicin and colistin were the most active bactericidal agents evaluated; tigecycline had potent activity by MIC but was largely bacteriostatic. In contrast, the high MBC 50/90 values for the other antibiotics evaluated reflected their decreased activities against this panel of isolates. Time-kill assays confirmed the potent bactericidal activity of plazomicin, where rapid and sustained 3-log killing at concentrations at or greater than 4-fold the MIC was observed. Plazomicin displays potent in vitro activity that further translates to rapid and sustained bacterial killing at lower concentrations than comparator agents in this study. Bactericidal activity at lower concentrations could be an advantage for a new antibacterial agent, as this prevents bacterial regrowth and presumably resistance emergence (16) . That this set of organisms is MDR highlights the clinical potential of plazomicin against isolates with challenging resistance phenotypes.
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